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Opinion statement
IgG4-related disease (IgG4-RD) is a multisystem inflammatory disorder. Early recognition
of IgG4-RD is important to avoid permanent organ dysfunction and disability. Neurological
involvement by IgG4-RD is relatively uncommon, but well recognised—hypertrophic
pachymeningitis and hypophysitis are the most frequent manifestations. Although the
nervous system may be involved in isolation, this more frequently occurs in conjunction
with involvement of other systems. Elevated circulating levels of IgG4 are suggestive of
the condition, but these are not pathognomonic and exclusion of other inflammatory
disorders including vasculitis is required. Wherever possible, a tissue diagnosis should be
established. The characteristic histopathological changes include a lymphoplasmacytoid
infiltrate, storiform fibrosis and obliterative phlebitis. IgG4-RD typically responds well to
treatment with glucocorticoids, although relapse is relatively common and treatment with
a steroid-sparing agent or rituximab may be required. Improved understanding of the
pathogenesis of IgG4-RD is likely to lead to the development of more specific disease
treatments in the future.
Introduction
IgG4-related disease (IgG4-RD) is a systemic, immune-
mediated fibro-inflammatory disease of unknown
cause, characterised by unique pathological features in-
volving a wide variety of organs [1, 2••, 3, 4].
Once regarded as an isolated single-organ disease,
IgG4-related disease is now recognised as a single mul-
tisystem disorder which can affect virtually any organ
system (Table 1) [5•, 6]. Clinically, enlargement of the
affected organ(s) may be accompanied by high serum
levels of IgG4, and the histology shows the classic
triad—infiltration of IgG4-bearing plasmacytes,
storiform fibrosis and obliterative phlebitis [5•, 7]. Its
protean manifestations mean it can mimic many other
conditions, including neoplastic, infectious and other
inflammatory diseases. These require exclusion if treat-
ment for this eminently treatable condition is to be
optimised [8, 9•, 10••].
The organs commonly affected by IgG4-RD are the
pancreas (autoimmune pancreatitis), bile ducts (scle-
rosing cholangitis), retroperitoneum (retroperitoneal
Table 1. Isolated tissue involvement by IgG4-RD is now recognised to occur as part of a multisystem disorder
Disease name Target organ
IgG4-related orbital disease Orbits and periorbital tissue
IgG4-related sialadenitis (Mikulicz’s disease, Küttner’s tumour) Salivary, lacrimal and
submandibular glands
IgG4-related thyroiditis (Riedel’s thyroiditis) Thyroid
IgG4-related sinusitis/midline destructive lesion/pharyngitis Ear, nose and throat
IgG4-related lung disease Lungs
IgG4-related pleural disease Pleura
IgG4-related mediastinitis Mediastinum
IgG4-related mastitis Breast
IgG4-related periaortitis Aorta
IgG4-related retroperitoneal fibrosis (Ormund’s disease) Retroperitoneum
IgG4-related cardiac disease Heart and pericardium
IgG4-related sclerosing mesenteritis Mesentery
IgG4-related autoimmune pancreatitis (type 1) Pancreas
IgG4-related sclerosing cholangitis Bile ducts
IgG4-related hepatitis Liver
IgG4-related gastrointestinal disease Gastrointestinal tract
IgG4-related interstitial nephritis/glomerulonephritis (idiopathic hypocomplementemic
tubulointerstitial nephritis with extensive tubulointerstitial deposits)
Kidney
IgG4-related prostatitis Prostate
IgG4-related epididymo-orchitis Testis
IgG4-related hypophysitis Hypophysis
IgG4-related pachymeningitis Dura mater
IgG4-related neuropathy Peripheral nerves
IgG4-related lymphadenopathy Lymph nodes
IgG4-related skin disease Skin
IgG4-related disease of the bone Bone
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fibrosis), salivary glands (sclerosing sialadenitis) and
lacrimal glands (dacryoadenitis). The nervous system
is less commonly involved, although a variety of man-
ifestations are recognised [11, 12].
The first report of central nervous system
(CNS) involvement by IgG4-RD occurred in the
context of hypophysitis [13], but since then,
hypertrophic pachymeningitis has also been
recognised to occur as part of the IgG4-RD spec-
trum, and IgG4-RD may account for a substantial
percentage of cases previously regarded as idio-
pathic [14, 15]. Here, we focus on the clinical
features, diagnosis and management of the neuro-
logical manifestations of IgG4-RD, which, although
uncommon, may be a life-threatening manifesta-
tion of a treatable disease.
History
In 1961, Sarles et al. raised the possibility that chronic inflammatory sclerosis of
the pancreas was a distinct clinical entity [16]. However, it was not until 1995
that Yoshida et al. suggested the concept of autoimmune pancreatitis based on
the clinical features of serum autoantibodies, hypergammaglobulinemia, occa-
sional association with other autoimmune diseases, histological evidence of
lymphoplasmacytic inflammation and fibrosis and a favourable response to
glucocorticoid treatment [17]. In 2001, Hamano et al. described high serum
IgG4 concentrations in patients with sclerosing pancreatitis, but not in patients
with pancreatic carcinoma, non-specific chronic pancreatitis, primary biliary
cirrhosis, primary sclerosing cholangitis and normal individuals—a condition
now known as type 1 (IgG4-related) autoimmune pancreatitis (AIP) [7].
Although reports had previously reported the coincidence of the number of
apparently isolated diseases—for example the case described by Montefusco
et al. with sclerosing cholangitis, chronic pancreatitis and Sjögren’s syndrome
[18]—the systemic nature of IgG4-RD has only been truly appreciated since
Kamisawa et al. proposed the clinicopathological entity ‘IgG4-related autoim-
mune disease’ with pancreatic, bile duct, retroperitoneal and salivary gland
involvement in 2003 [13, 19–29].
Epidemiology
Few large-scale epidemiological studies of IgG4-RD have been performed,
and the majority have focused on AIP in Japanese cohorts [30]. In contrast
to other autoimmune diseases, a male predominance of IgG4-RD has been
reported, with a peak onset of disease at 61–70 years [31]. In keeping with
the more recent and widespread recognition of the condition, four studies
describing relatively large cohorts of patients with IgG4-RD have been
published within the last 2 years: three retrospective and one prospective,
with two originating from the USA, one from China and one from Japan
[32, 33, 34••, 35]. The main demographic and clinical findings are
summarised in Table 2. In all studies, neurological disease was relatively
rare, although cases of pituitary, meningeal and peripheral nervous system
involvement were reported. In two smaller European studies, one from
Spain and the other one from Italy, pachymeningitis was the only reported
neurological manifestation—2/55 (4%) and 3/41 (7%), respectively [36, 37].
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Pathophysiology
IgG4 is one of the four human IgG subclasses and usually constitutes G5% of
IgG in healthy individuals [38]. Despite having over 90% amino acid sequence
homology with the other subclasses, IgG4 has a unique structure and function
and is generally regarded as non-inflammatory because it does not efficiently
engage activating Fc receptors or complement andmight be functionally mono-
valent in vivo [39]. Although IgG4 autoantibodies are known to be pathogenic
in a number of diseases including pemphigus vulgaris, thrombotic thrombocy-
topenic purpura and idiopathic membranous nephropathy, there is growing
acceptance that IgG4 itself is unlikely to be pathogenic in IgG4-RD [2••, 40, 41].
Indeed, the effectiveness of B cell depletion therapy in IgG4-RD suggests that
B lymphocytes and other cells of this lineage play an important pathological
role, probably via their interaction with CD4+ cytotoxic T lymphocytes (CTL)
serving as effective antigen-presenting cells and/or through the secretion of B
cell-derived growth factors [42, 43].
Table 2. Summary findings of four cohorts of patients with IgG4-RD published within the last 2 years [32, 33,
34••, 35]
Lin et al.
(n = 118)
Wallace et al.
(n = 125)
Inoue et al.
(n = 235)
Sekiguchi et al.
(n = 166)
Type of study Prospective Retrospective Retrospective Retrospective
Age, mean (range, years) 53.1 (19–80) 55.2 (24–83) 67 (35–86) 61 (49–70)
Men/women, n (%) 82 (69)/36 (31) 76 (61)/49 (39) 189 (80)/46 (20) 125 (75)/41 (25)
Single organ/≥2 organs (%) 4.2/95.8 38/62 42/58 20/80
Organ involvement, n (%)
Pancreas 45 (38.1) 24 (19.2) 142 (60) 107 (64.5)
Bile ducts 21 (17.8) 12 (9.6) 31 (13) 93 (56)
Lacrimal glands 60 (50.8) 28 (22.4) orbitsa 53 (23) 14 (8.4)
Salivary glands 76 (64.4) 35 (28) 81 (34) 16 (9.6)
Lymphadenopathy 77 (65.3) 34 (27.2) 34 (14) 29 (17)
Retroperitoneal fibrosis/periaortitis 31 (26.3) 37 (29.6) 57 (24) 24 (14.5)
Kidney 29 (24.6) 15 (12) 54 (23) 21 (12.7)
Lungs 32 (27.1) 22 (17.6) 31 (13) 23 (13.9)
Prostate 29 (24.6) 4 (3.2) –a 3 (1.8)
Pituitary 2 (1.7) None –a 2 (1.2)
Meninges None 3 (2.4) None None
Peripheral nerves None 1 (0.8) –a None
aReported as other sites (3%)—prostate, peripheral nerve, pituitary gland, skin and pericardium
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Plasmablasts (CD19+CD20−CD27+CD38+) are found in high concentra-
tions in IgG4-RD, regardless of the serum IgG4 concentration, and their number
may correlate more strongly with disease activity than IgG4 levels [44]. Circu-
lating oligoclonal plasmablasts demonstrate intense somatic hypermutation,
supporting the idea that T helper cell-dependent processes are likely to be
important in IgG4-RD pathophysiology [45]. How and why specific B cells
are recruited to become clonally expanded IgG4-producing plasmablasts and
plasma cells remains unknown, but T follicular helper cells appear to drive the
class switch towards IgG4, perhaps through the secretion of IL-4 (amongst other
cytokines) [41, 45].Wenniger et al. recently confirmed highly abundant IgG4+ B
cells and plasma cell clones (through analysis of the B cell receptor heavy chain)
in blood and tissue of patients with active IgG4-related cholangitis; these
disappeared with corticosteroid treatment, suggesting that specific B cell re-
sponses may be pivotal to the pathogenesis of IgG4-RD [46]. Furthermore,
the presence of oligoclonal IgG4 bands in the cerebrospinal fluid (CSF) of
subjects with IgG4-related hypertrophic pachymeningitis supports the concept
of an antigen-driven immune response [47, 48].
On the other hand, CD4+ T cells have been shown to be dispersed throughout
IgG4-RD lesions and to be the most abundant cell within affected tissues [4, 5•,
12, 49]. The recent characterisation of a clonally expanded population of CD4+
CTL in both the peripheral blood and fibrotic lesions of IgG4-RD patients
suggests that these cells are indeed central to the disease pathogenesis [41, 43,
49]. Mattoo et al. demonstrated that CD4+ CTL cells which also expressed
signalling lymphocytic activation molecule F7 (SLAMF7) were expanded in
patients with IgG4-RD, and these cells expressed granzyme B, perforin, IL-1β,
TGF-β and IFN-γ, which may be important mediators of tissue damage [43].
Rituximab-induced clinical remission was associated with a reduction in the
number of these CD4+ CTL, but had minimal or no effect on the frequency
and number of CD4+GATA3+ Th2 phenotype cells or CD4+CD25+Foxp3+ regu-
latory T cells [49]. The CD4+ CTL do not express surface CD20, which adds
further support to the hypothesis that CD4+ CTL are sustained by cells of B cell
lineage [41].
Th1/Th2/Treg cells have been variably implicated in IgG4-RD pathophysiol-
ogy, but direct evidence for their role is lacking, and Th2 cells may only accumu-
late in those with IgG4-RD and concomitant atopy [42, 50].
In summary, CD4+ CTL may orchestrate IgG4-RD, but be themselves
sustained by continuous antigen presentation by B cells or by B cell-dependent
growth factors, self-perpetuating an immune response against a specific antigen
(whether microbial, environmental or self) [41, 42]. Further characterisation of
the pathogenesis of the condition may offer an opportunity for a more rational
and targeted therapeutic approach in the future, e.g. elotuzumab, a humanised
monoclonal antibody directed against SLAMF7 and approved for patients with
relapsed/refractory multiple myeloma [51].
Neurological manifestations of IgG4-RD
The most common CNS manifestations of IgG4-RD are hypertrophic
pachymeningitis and hypophysitis, although direct parenchymal brain involve-
ment and changes secondary to associated vasogenic oedema have been
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reported as well as inflammatory pseudotumour [52]. IgG4-related neuropathy
and IgG4-related perineural disease have been reported, but occur relatively
infrequently.
IgG4-related pachymeningitis
Pachymeningitis secondary to IgG4-RD is a form of hypertrophic
pachymeningitis characterised by localised or diffuse inflammation and thick-
ening of the meninges (mostly dura mater)—cerebral, spinal or rarely both [15,
53–55]. Infectious, inflammatory and neoplastic causes need to be considered.
Of the inflammatory causes, sarcoidosis, granulomatosis with polyangiitis
(GPA), rheumatoid arthritis (RA), Sjögren’s syndrome and IgG4-RD are the
most common [15, 54, 55]. The prevalence of hypertrophic pachymeningitis
has been evaluated in a Japanese national survey and reported to be 0.949 cases
per 100,000, with pachymeningitis due to IgG4-RD being observed in 8.8%,
second only to anti-neutrophil cytoplasmic antibody (ANCA)-related
pachymeningitis [56]. Hypertrophic pachymeningitis in IgG4-RD was more
commonly seen in men (1:0.17), and the mean age of onset was 56.7 years.
Symptoms arising due to hypertrophic pachymeningitis occurring in the
context of IgG4-RD typically reflect either focal or widespread meningeal in-
volvement (e.g. hemispheric or basal dura), leading tomechanical compression
of structures (e.g. cranial palsies) or to more diffuse symptoms (e.g. headache,
seizures and cognitive decline) [55, 57]. Indeed, chronic headache andmultiple
cranial neuropathies are the most commonly reported symptoms [15, 53, 55,
57, 58]. Symptoms resulting from mechanical compression are dependent on
anatomical location. Where there is involvement of the cavernous sinus or
superior orbital fissure, possible manifestations include paresis of the cranial
nerves II–VI and a combination of retro-orbital pain, altered vision and extra-
ocular muscle palsies, such as the Tolosa–Hunt syndrome [15, 54, 59–66].
Involvement of the middle fossa, falcotentorial, cerebellar tentorium and pos-
terior fossa areas typically causes paresis of the cranial nerves VI–XII and/or
cerebellar ataxia [15, 53, 54, 67–70]. Lesions in the vertebral canal are more
common at the cervical and thoracic levels and may present with
radiculopathies, limb paresis and/or sphincter disturbances [54, 59, 71–75].
IgG4-related leptomeningitis has been reported in three patients [14, 76, 77],
although the possibility that this may occur due to rheumatoid meningitis rather
than IgG4-RD should be considered, particularly given the similarity in histopa-
thology; two patients were known to have concomitant RA and the third had
significantly elevated anti-CCP antibodies without clinical features of RA (al-
though detection of anti-CCP antibodies can precede the emergence of clinical
features of RA by many years) [15].
In 2014, Lu et al. reviewed 33 cases of biopsy-proven IgG4-related
hypertrophic pachymeningitis, and the presenting features were as follows:
headache (67%), cranial nerve palsies (33%), visual disturbance (21%,
typically diplopia or decreased visual acuity), motor weakness (15%), limb
numbness (12%), sensorineural hearing loss (9%), seizures (6%) and
cognitive decline (3%) [57]. About 48% had systemic involvement, mostly
bone (12%), salivary glands (9%), lungs (9%), kidney (6%), orbital
pseudotumour (6%) and retroperitoneal fibrosis (6%). Isolated IgG4-
related hypertrophic pachymeningitis was present in 30% of the patients,
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although, notably, systemic involvement could not be excluded in 27%
due to lack of available information.
IgG4-related hypophysitis
Hypophysitis secondary to IgG4-RD is one of the most recently described
forms of hypophysitis and is defined by an inflammatory process of the
pituitary gland that can involve contiguous structures [78]. As with AIP,
patients with IgG4-related hypophysitis tend to be middle-aged and older
men [14, 71, 79–81].
IgG4-related hypophysitis most often presents with panhypopituitarism
[81], although anterior hypopituitarism with a combination of hormone
deficiencies or diabetes insipidus has also been reported [49, 82, 83]. A
predictable constellation of symptoms resulting from pituitary insufficien-
cy may occur (e.g. general malaise, loss of appetite, weight loss, polyuria,
polydipsia, amenorrhoea and decreased libido), but neither these nor the
symptoms which may arise due to compression of nearby structures are
themselves specific to IgG4-RD; alternative underlying aetiologies includ-
ing Langerhans cell hystiocytosis, sarcoidosis, GPA, infection, neoplasia
and iatrogenic causes, such as treatment with interferon or anti-cytotoxic
T lymphocyte-associated protein 4 (CTLA-4), need to be considered. How-
ever, clues as to the underlying diagnosis may be apparent from the
concurrence of systemic features of IgG4-RD, such as retroperitoneal fibro-
sis, salivary gland disease and lymphadenopathy. Indeed, isolated
hypophysitis secondary to IgG4-RD appears to be relatively uncommon,
although the limitations of the available data are noted.
Although hypophysitis secondary to IgG4-RD has been considered a
rare condition, Bando et al. recently screened 170 consecutive outpatients
presenting with hypopituitarism and/or diabetes insipidus and reported
that a diagnosis of IgG4-RD was made in 30% with hypophysitis, 22%
with hypopituitarism/diabetes insipidus and 4% of all cases of hypopitu-
itarism and/or diabetes insipidus [84]. Bernreuther et al. retrospectively
determined the prevalence of hypophysitis secondary to IgG4-RD amongst
cases previously diagnosed as primary hypophysitis (lymphocytic
hypophysitis, granulomatous hypophysitis and hypophysitis not otherwise
specified), and the histological and immunohistochemical analysis of all
cases revealed that 41.4% (12/29) of cases previously diagnosed as prima-
ry hypophysitis fulfilled the criteria for IgG4-RD [85].
Inflammatory pseudotumour
Inflammatory pseudotumour is a descriptive term for a family of lesions with
diverse aetiology characterised by a tumour-like mass lesion which may mimic
neoplastic disease [86]. Histopathological analysis demonstrates hyalinized
collagenous tissue admixed with a lymphoplasmacytic infiltrate, composed
chiefly of polyclonal plasma cells, lymphocytes and scattered histiocytes with
or without eosinophils [86, 87].
Themost common anatomical sites for IgG4-related pseudotumours are the
orbit, salivary glands, lungs, kidneys, lymph nodes and retroperitoneum. Al-
though involvement of the nervous system appears to be relatively rare, a range
of sites have been noted including involvement of the meninges (mimicking
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meningioma), ventricles, parietotemporal parenchyma, pituitary gland, cranial
nerves and spinal cord [87–94]. Symptoms typically arise due to the compres-
sive nature of these lesions and therefore depend on their location.
Parenchymal brain involvement
Biopsy-proven parenchymal brain involvement in the absence of
pseudotumour formation has been reported infrequently and in association
with pachymeningitis or systemic IgG4-RD. Regev et al. reported biopsy-proven
involvement of the brain parenchyma in a patient with systemic manifestations
of IgG4-RD [52]. Magnetic resonance imaging (MRI) showed multifocal high
signal abnormalities on T2 and fluid-attenuated inversion recovery sequences
with subtle enhancement with gadolinium. Parenchymal brain involvement is
reported in a small number of additional cases, although all were associated
with pachymeningitis (Fig. 1) [95–97]. Two had biopsy-proven parenchymal
involvement, whilst the other had pachymeningitis secondary to biopsy-proven
IgG4-RD with high signal in the overlying temporal lobe. In the latter case,
Fig. 1. MR imaging (a, b) demonstrated an enhancing soft tissue mass involving the right posterior nasopharynx with infiltration
laterally and posteriorly into the right prevertebral strap muscles and through the pharyngobasilar fascia to involve the medial and
lateral pterygoids. The right carotid and internal carotid artery was ensheathed and abnormal tissue was seen in the right carotid
canal and jugular foramen. The right cavernous sinus was involved via perineural spread through the foramen ovale. Basal pachy-
and leptomeningitis were noted along the floor of the right middle cranial fossa with high signal in the overlying temporal lobe (c).
Progressive changes were noted in the pterygomaxillary fissure, the muscles of the masticator compartment and throughout the
temporalis muscle on the right at the time of representation (d). e–g A diffuse plasma cell-rich, chronic inflammatory cell infiltrate
with prominent stromal fibrosis/hyalinization, fat necrosis and focal granulation tissue was evident on biopsy of the anterior
temporalis and posterior maxilla (e). Immunocytochemistry demonstrated numerous IgG- and IgG4-positive plasma cells (f, g).
Reproduced with permission from Rice et al. [95].
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biopsy of the brain parenchyma was not undertaken, and the possibility re-
mains that the imaging abnormalities which were not associated with clinical
signs were due to vasogenic oedema rather than direct brain involvement.
IgG4-related neuropathy and perineural disease
Inoue et al. retrospectively studied 106 patients with IgG4-RD and identified
seven with a total number of 21 peripheral nerve lesions [98]. A number of
other authors have also reported perineural disease secondary to IgG4-RD
[99, 100]. Typically, this has occurred in orbital or paravertebral areas and the
lesions have been asymptomatic, indolent and steroid-responsive, although
they necessitate differentiation from other potentially aggressive conditions
such as lymphoma, neurogenic tumours, sarcoidosis and idiopathic inflam-
matory pseudotumour. Radiologically, a distinct, perineural soft tissue mass
has been reported. Histological analysis of the epineuriumhas been available
in only a limited number of cases , but demonstrates massive
lymphoplasmacytoid infiltrate which is rich in IgG4+ plasma cells and pref-
erentially involves the epineurium.
To the best of our knowledge, there is only a single report of neuropathy
ascribed to IgG4-RD [101]. The authors described a 55-year-old man with
histopathologically confirmed IgG4-RD manifesting as mononeuritis multi-
plex, with electrophysiological findings suggestive of axonal neuropathy.
Histopathological analysis of the sural nerve demonstrated marked thicken-
ingwith abundant collagen fibres and infiltration of IgG4+ plasma cells in the
epineurium, a moderate degree of myelinated fibre loss, but no evidence of
vasculitis. Oral prednisolone was highly effective, with rapid improvement
of the neuropathic symptoms.
Recently, Kamiya et al. described an intriguing case of a 68-year-old man
who presented with concomitant biopsy-proven IgG4-related sialadenitis
and cryoglobulinaemic vasculitis in the context of lymphoma which was in
remission [102]. The cryoglobulins were predominantly monoclonal IgG-κ,
and biopsies of the skin and sural nerve were more consistent with vasculitis
rather than IgG4-RD. The link (if any) between the concomitant IgG4-RD
and cryoglobulinaemia remains unclear.
Diagnostic approach
IgG4-RD is a clinicopathological diagnosis incorporating features from the
history and clinical examination, as well as serological, radiological and
histopathological investigations. In 2011, diagnostic criteria were pro-
posed and consisted of (1) characteristic diffuse/localised swelling or
masses in single or multiple organs; (2) elevated serum IgG4 concentra-
tions; and (3) histopathology demonstrating infiltration of lymphocytes
and plasmacytes with demonstration of IgG4+ plasma cells (ratio of IgG4+/
IgG+ cells 940% and 910 IgG4+ plasma cells/high-power field, HPF) and
fibrosis [103]. The diagnosis is deemed definite if all the above features are
present, probable if (1) plus (3) are present and possible if (1) plus (2) are
present. Yamamoto et al. validated these criteria using a registry cohort
that consisted mainly of patients with dacryoadenitis and sialadenitis
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[104], but they have not otherwise been widely used, as yet.
When confirming the involvement of the nervous system due to IgG4-
RD, the approach is similar. However, the diagnostic workup may also
include analysis of the CSF; depending on the location of the lesion, there
may be greater reticence when considering tissue biopsy, and in some cases
with multi-organ involvement, CNS biopsy may not be required. In others,
such as those with isolated hypertrophic pachymeningitis, for example,
histological analysis is required [57].
Leporati et al. devised specific diagnostic criteria for hypophysitis sec-
ondary to IgG4-RD, which permitted diagnosis when MRI of the pituitary
was compatible and there was histopathological evidence from another
organ or, if that was not possible, increased serum IgG4 levels and prompt
response to corticosteroid therapy [82]. These criteria have not been inde-
pendently verified, but they have been widely used in practice.
Where definitive diagnosis cannot be made, careful consideration of the
differential diagnosis must be undertaken. Of these, it is worth considering
ANCA-associated vasculitis (particularly GPA) as it shares many of the
multisystem features of IgG4-RD, including pachymeningitis and
hypophysitis [49, 105, 106]. Furthermore, increased serum levels of IgG4
and infiltrating IgG4+ plasma have also been described in GPA [15, 107–
109]. Nonetheless, there are some noteworthy differences [49]. The major-
ity of patients with GPA have nasal disease, although some may be
subclinical. This may manifest as bloody nasal crusts, nasal septal mucosal
erosions and sinus disease. IgG4-RD is less likely to lead to erosive
sinonasal disease, usually manifesting with allergic features and, occasion-
ally, nasal masses. In the lungs, GPA more commonly leads to nodular or
cavitating lesions, alveolar haemorrhage or bronchial stenosis, and IgG4-
RD typically causes pleuritis, nodular pulmonary lesions, ground-glass
infiltrates, interstitial fibrosis and/or thickening of bronchovascular bun-
dles. The renal manifestations of GPA and IgG4-RD are also distinguish-
able as IgG4-RD is characterised by tubulointerstitial nephritis (only rarely
by membranous nephropathy) and GPA typically presents with crescentic
and necrotizing glomerulonephritis. Serologically, both may be associated
with high serum levels of IgG4, but GPA is usually ANCA-positive with
antigen specificity for proteinase 3 (less often for myeloperoxidase), and
ANCA is typically negative in IgG4-RD. Indeed, although ANCA positivity
does not exclude the diagnosis of IgG4-RD, it should prompt the exclusion
of a concomitant vasculitic process [105]. Histologically, GPA is usually
associated with foci of necrosis, granulomatous inflammation and giant
cells, and neutrophils invariably constitute a prominent part of the infil-
trate, features not seen in IgG4-RD [110].
Below, we will review components of the diagnostic approach to IgG4-
RD, with specific reference to the neurological manifestations of the
disease, particularly pachymeningitis and hypophysitis.
Presentation
None of the neurological manifestations of IgG4-RD are pathognomonic, and
theymay occur in the context of systemic disease or, less commonly, in isolation.
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IgG4-RD usually follows a relapsing–remitting course and may occur, either
synchronously or metachronously, in a variety of organs, including the pancreas,
bile duct, lacrimal glands, periorbital tissues (e.g. the lacrimal gland and retro-
orbital space), thyroid, central and peripheral nervous systems, lung, pleura,
heart, pericardium, breast, liver, gastrointestinal tract, kidney, prostate gland,
retroperitoneum lymph nodes and skin [1, 2••, 3, 4, 5•, 6, 111–113]. Typically,
one organ dominates the clinical picture, and the symptoms are dependent upon
the location of the lesions occurring as a consequence of organ swelling with or
without compression of nearby structures or tissue damage resulting in loss of
function.
IgG4-RD tends to present indolently, with symptoms appearing over
months to years [114]. In addition, constitutional symptoms are often
subtle or even absent, and patients often feel relatively well even in the
setting of multi-organ disease [8, 79, 114]. However, a minority of patients
have a more fulminant presentation characterised by constitutional symp-
toms, fever and multi-organ involvement from the outset [4, 8]. A diffuse
array of musculoskeletal symptoms (e.g. arthralgias and enthesopathy) has
been reported, although no histopathological abnormalities of the
synovium or tenosynovium have been confirmed. A history of atopy is
sometimes reported [2••].
Radiology
Imaging studies in IgG4-RD are useful both for diagnostic and monitoring
purposes, although their limitations in the exclusion of other causes of
pachymeningitis and hypophysitis have already been highlighted.
On computed tomography (CT) scans and MRI studies, hypertrophic
pachymeningitis occurring in the context of IgG4-RD may appear either as
a linear dural thickening or as a focal mass, and it may be localised or
diffuse [54, 57, 115, 116]. The focal or pauci-focal distribution of changes
within the meninges seems to be more frequent in pachymeningitis due to
IgG4-RD, although this observation is based on a limited number of
patients [15].
On T2-weighted MRI, fibrotic hypertrophic meninges are thickened and
relatively hypointense, with foci of hyperintensity being suggestive of
inflammation that can be confirmed using gadolinium-enhanced T1-
weighted MRI [57, 115, 116]. Conversely, CT scans are more useful in
the assessment of concomitant bone involvement, and on CT studies,
dural lesions typically appear thickened, hyperdense and contrast-
enhanced [57]. In general, MRI is superior to CT for the anatomical
evaluation of the optic chiasm, nerve roots, brainstem and skull base,
and gadolinium-enhanced T1-weighted MRI studies may also offer superi-
or spatial resolution and facilitate the identification of active inflammation
along the dural edges.
Pituitary stalk enlargement is the most common finding on MRI of
hypophysitis secondary to IgG4-RD, although there may be isolated in-
volvement of the pituitary, concomitant involvement of the pituitary and
stalk, and/or pseudotumour formation [80, 81, 83, 84, 116, 117]. The
pituitary lesions are usually hypointense on T2-weighted imaging and
show homogeneous contrast enhancement on T1-weighted images [116–
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123]. Absence of pre-contrast T1 hyperintensity in the posterior pituitary
gland may suggest central diabetes insipidus, although this requires
confirmation through endocrinological workup [116]. Associated
pachymeningitis is occasionally seen [115, 117].
Nuclear medicine
In recent years, 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomogra-
phy–computed tomography (FDG PET-CT) has emerged as a potentially useful
tool in the diagnosis and monitoring of IgG4-RD [47, 68, 71, 80, 124–128]. In
2014, Ebbo et al. retrospectively analysed 21 patients with IgG4-RD and con-
cluded that FDGuptake is correlatedwith the disease activity and improves after
treatment [124]. The authors also suggested that FDG PET-CT might be more
sensitive than conventional radiologic imaging to detect IgG4-RD involvement,
although exceptions were reported; a patient with pachymeningitis identified
on MRI and two cases with nodular infiltration of the kidney on CT had no
detectable abnormality of FDG uptake. These false negative results could be
explained by (1) the physiologic fixation of FDG in the brain and kidneys, with
failure to detect lesions contiguous to these organs, and/or (2) the limited
spatial resolution of PET-CT as the lesion in the ‘missed’ case of
pachymeningitis was very small. Others have suggested that, for the evaluation
of intracranial meningeal lesions, carbon 11-labelled methionine may be pref-
erable because of its low uptake in the normal brain [129].
Recently, Lee et al. assessed the diagnostic utility of FDG PET-CT in the
differential diagnosis of IgG4-RD. The authors compared data from28 IgG4-RD
patients with 66 patients with other diseases (mainly malignancy and inflam-
matory diseases) [127]. Statistical analysis revealed three variables with greater
discriminatory power: maximum standardised uptake value (SUVmax) of main
involved organ (typically mild to moderate and lower than that of other
diseases); SUVmax of submandibular glands (higher FDG uptake when com-
paredwith other diseases); and presence ofmulti-organ involvement. There was
a substantial degree of overlap between the distribution of tissue involvement
between IgG4-RD and other diseases, but in this study, FDG PET-CT had a
diagnostic sensitivity of 85.7% and a specificity of 66.1% for IgG4-RD.
It is also worth noting that gallium SPECT/CT may also have potential
clinical utility in the diagnosis and monitoring of IgG4-RD, particularly given
its lower cost and more widespread availability [130].
Laboratory analyses
Serum inflammatorymarkers such as the erythrocyte sedimentation rate and C-
reactive protein may be modestly elevated in IgG4-RD [114]. Occasionally, a
polyclonal gammopathy with high serum IgG and IgE can be found, along with
hypocomplementaemia (mostly in the setting of tubulointerstitial nephritis)
and peripheral eosinophilia [29, 111, 114].
Elevated serum IgG4 concentrations are characteristic of IgG4-RD. Nonethe-
less, serum IgG4 has shortcomings both as a diagnostic marker and in moni-
toring disease activity or predicting disease relapse. For diagnostic purposes, it is
neither necessary nor sufficient to confirm a diagnosis of IgG4-RD on its own,
although when present it is supportive. Serum IgG4 concentrations tend to be
higher in patients withmulti-organ involvement [27, 131–135]. However, high
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serum levels of IgG4 have been reported in healthy individuals and in patients
with parasitic diseases, allergic disease, autoimmune diseases including RA,
ANCA-associated vasculitis and multicentric Castleman’s disease, as well as
certain malignancies (particularly pancreatic), and most of these diseases can
bemimickers of IgG4-RD [114, 134, 136–139]. Furthermore, depending on the
series, as many as 45% of patients with biopsy-proven IgG4-RD may have
normal serum IgG4 concentrations at the time of diagnosis, and this may be
of particular relevance to those with isolated hypertrophic pachymeningitis,
who may have increased intrathecal IgG4 despite normal serum levels of IgG4
[3, 33, 47, 131, 140].
A recent meta-analysis reported that high serum IgG4 (9135 mg/dL) has a
pooled sensitivity of 87.2% and a specificity of 82.6% for the diagnosis of IgG4-
RD, although significant heterogeneity was observed [141]. Doubling the cutoff
value for IgG4 improved the specificity to 94.8%, at the expense of the sensi-
tivity, which was reduced to 63%. A recent prospective UK cohort found similar
diagnostic sensitivity and specificity for serum IgG4, with higher levels being
associated with multi-organ involvement and risk of relapse and its levels
falling with corticosteroid therapy [134]. In this cohort, IgG4-RD diagnostic
criteria were met in only 5.1% (58/1140) of patients who had serum IgG4
measured for the purpose of discriminating IgG4-RD from other disease con-
ditions and in only 22.4% (48/214) of patients who had an elevated serum
IgG4. One explanation for some false negative results is the ‘prozone
effect’—underestimation of the serum IgG4 concentration in the presence of
large antigen excessmay occur when nephelometry assays are used, but diluting
the samples can prevent this from happening [142]. In the study by
Khosroshahi et al., the prozone effect led to falsely low serum IgG4 concentra-
tions in 26% of patients tested, and this effect was more likely to occur in
patients with active disease [142]. Therefore, one must not rely exclusively on
serum IgG4 levels to diagnose IgG4-RD.
The ability of serum IgG4 levels to predict relapses and effectively
monitor treatment response is controversial—for example, in the study
reported by Kamisawa et al., the relapse rate was 30% in those with
persistently elevated IgG4 levels and 10% in those with normal concen-
trations [143, 144].
More recently, Wallace et al. showed that circulating plasmablasts are
elevated in active IgG4-RD (even in patients with normal serum IgG4
concentrations) and that plasmablast counts are a potentially useful bio-
marker for diagnosing IgG4-RD and assessing its response to treatment
[44]. Measurements of peripheral blood plasmablasts may be particularly
useful for those patients with normal serum IgG4 concentrations but high
clinical suspicion for active IgG4-RD, especially if a biopsy is not feasible
and appropriate measures have been undertaken to exclude malignancy
[44]. Although, intuitively, this approach may have particular advantages
for the subset of patients with isolated neurological manifestations of
IgG4-RD, there are no data available to confirm or refute this.
CSF analysis
CSF analysis is of particular importance with regard to IgG4-RD, not only
because it offers the possibility to make a positive diagnosis of disease
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mimics and may give specific information about intrathecal synthesis of
IgG4. CSF evaluations in patients with pachymeningitis secondary to IgG4-
RD generally reveal clear fluid with normal glucose concentration, normal
to mildly increased protein levels and a variable degree of lymphocytic
pleocytosis [15, 145]. However, such findings are not specific and cannot
differentiate pachymeningitis secondary to IgG4-RD from other forms. The
first reports of intrathecal IgG synthesis with an oligoclonal pattern and
prominent intrathecal IgG4 production (high IgG4 level and IgG4 index)
were from Della-Torre et al. [47, 48]. These authors described the CSF
findings of three patients with pachymeningitis secondary to IgG4-RD. All
had oligoclonal bands with high IgG4 index at baseline, which, where
examined, normalised after treatment. Subsequently, Della-Torre et al.
compared the findings of these three patients with nine controls and 21
patients with hypertrophic pachymeningitis due to alternative causes and
concluded that quantification of CSF IgG4 may be a diagnostic tool,
particularly when serum and CSF IgG4 concentrations were interpreted
in relation to the blood–CSF barrier [145].
Histopathology
Definitive diagnosis of IgG4-RD requires an appropriate histological ap-
pearance with increased numbers of IgG4+ plasma cells (or an elevated
IgG4/IgG ratio) in tissue [5•, 14, 110]. The key morphologic features of
IgG4-RD histology are the following: (1) a dense lymphoplasmacytic
infiltrate; (2) fibrosis that is organised in a storiform pattern; (3) obliter-
ative phlebitis; and a (4) mild-to-moderate eosinophil infiltrate [5•, 110].
In the majority of cases, these include a dense lymphoplasmacytic infiltrate
and storiform-type fibrosis, but exceptions to this rule exist. In organs such
as the lymph node, kidney, and the salivary and lacrimal glands, storiform-
type fibrosis or obliterative phlebitis may be inconspicuous or absent [5•].
The most specific histological finding seems to be obliterative phlebitis,
although this appears not to be particularly prominent in neurological
IgG4-RD [14, 15, 84, 85].
The inflammatory lesion frequently forms a tumefactive mass that may
destroy the involved organ, and the inflammatory infiltrate is composed of
a mixture of T and B lymphocytes. T lymphocytes predominate in the
infiltrate and are usually present diffusely, whilst B cells tend to be located
within lymphoid aggregates or even germinal centres [5•]. Semiquantita-
tive analysis of IgG4 immunostaining typically reveals the presence of
more than 10 IgG4+ plasma cells/HPF or a ratio of IgG4+ plasma cells to
IgG+ plasma cells higher than 40%, but individualised cutoffs based on the
site of involvement may be required [5• , 110, 135]. For both
pachymeningitis and hypophysitis due to IgG4-RD, it is generally accepted
that the standard cutoff of 10 IgG4+ plasma cells per HPF is reasonable
[15]. A lower cutoff point for IgG4+ cells may be acceptable in cases with
the characteristic morphologic features [2••]. IgG4-RD is more difficult to
diagnose in the late phase of organ involvement, when fewer plasma cells
are present and fibrosis predominates (e.g. the retroperitoneum and
meninges)—the pattern of fibrosis and the ratio of IgG4 to total IgG
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provide crucial information in this context [135]. It must also be remem-
bered that infiltration of tissues with IgG4+ plasma cells is not specific for
IgG4-RD and should always be interpreted in light of the accompanying
clinical, histological, radiological and serological findings [110].
Treatment
Because of its rarity, treatment of neurological disease secondary to IgG4-RD
has been extrapolated from the relatively limited evidence available for even the
more common organ manifestations. No randomised clinical trials have been
performed in IgG4-RD, and the best evidence for therapeutic options comes
from systematic review of the literature (Brito-Zeron et al., for example) [9•]
and expert guidance [10••].
Not every patient with IgG4-RD needs treatment, and given that some cases
of spontaneous remissions have been reported, a ‘watchful-wait’ decision may
be appropriate in some patients (e.g. asymptomatic lymphadenopathy) [2••,
9•, 144, 146–148]. However, when vital organ involvement is present, it
usually requires aggressive and immediate treatment to prevent organ dysfunc-
tion and failure [2••, 9•, 41]. In 2015, an International Consensus Statement
on the Treatment of IgG4-RD recommended that all patients with symptomatic,
active disease require treatment [10••]. Increasingly, it is recognised that a
major determinant of treatment responsiveness is the degree of fibrosis within
the affected organs; untreated IgG4-RD often progresses from
lymphoplasmacytic inflammation to extensive fibrosis, and at this stage, pa-
tients are less likely to have a response to treatment [2••, 29, 148, 149].
Glucocorticoids are the first-line treatment, unless there is a contraindication
[10••, 147]. Patients with IgG4-RD (including those with neurological involve-
ment) usually have an excellent but often unsustained clinical response to
glucocorticoids [1, 8, 15, 29, 81, 82, 112, 143, 144, 150]. Responsiveness to
glucocorticoids is characteristic early in the disease course, before the onset of
significant tissue fibrosis ensues. In this respect, FDG PET-CT may have an
important role in defining the extent of the inflammation. Clinical responses
to glucocorticoids are usually quick (within 2 weeks) and are typically accom-
panied by a decline in serum IgG4 concentration [29, 140, 143, 144, 148].
However, this serological response to glucocorticoids is not specific for IgG4-RD
and should not be used to differentiate it from other conditions [134].
Relapse rates after steroid withdrawal are high, and may also be significant
during glucocorticoid taper or maintenance therapy [143, 144, 151, 152]. A
recent systematic review by Brito-Zéron et al. reported that treatments with first-
line glucocorticoid regimens were 97% effective, but carried a 33% risk of
relapse [9•]. Typically, relapses were themselves responsive to glucocorticoid
treatment, albeit at increased doses.
For remission induction of IgG4-RD, prednisolone at a dose of 30–
40 mg/day is commonly instigated [153]. However, for neurological
manifestations of IgG4-RD (mostly pachymeningitis), an initial course
of intravenous methylprednisolone (e.g. 500 mg–1 g for 3 days) has
been used in an attempt to rapidly and effectively dampen the inflam-
matory response and prevent irreversible CNS damage [47, 65, 71, 81,
112, 154], although some authors have reported positive outcomes with
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relatively low doses of glucocorticoids in pachymeningitis [96] and re-
placement therapy in hypophysitis [80, 81, 121, 128, 155, 156].
The dose and duration of ongoing glucocorticoid therapy are a matter
of ongoing debate. For example, some clinicians from Asia recommend
treatment with prednisolone 0.6 mg kg−1 day−1 for 2–4 weeks, followed
by a tapering schedule over a period of 3–6 months down to a mainte-
nance dose (2.5–5 mg/day), which is then maintained for up to 3 years.
These recommendations are mostly based on a study conducted by
Kamisawa et al. in AIP—23% of the patients on glucocorticoid mainte-
nance treatment relapsed versus 34% of the patients off treatment [143].
Relapse occurred within 6 months after starting treatment in 32%, within
1 year in 56% and within 3 years in 92%, leading the authors to suggest
prolonging maintenance treatment for 3 years. These observations have
not been reproduced in other studies, and taking into account the mor-
bidity associated with long-term steroid therapy and the steroid
responsiveness of relapse, some authors advocate discontinuation of glu-
cocorticoid treatment after 3–6 months of treatment [152, 157–159].
Nonetheless, certain patients do seem to benefit from maintenance of
glucocorticoid therapy, although the optimal dose and duration of the
treatment are uncertain [10••]. There is some evidence to suggest that
patients with multi-organ disease, significantly elevated serum IgG4 con-
centrations, involvement of the proximal bile ducts or a history of disease
relapse are at higher risk of early recurrence [144, 159]. Patients with
organ-threatening IgG4-RD (including hypophysitis and pachymeningitis)
may also benefit from long-term maintenance therapy in an effort to
minimise irreversible CNS damage [10••, 83].
Azathioprine, mycophenolate mofetil, methotrexate (MTX), 6-mercap-
topurine, tacrolimus and cyclophosphamide have been used as potential
‘steroid-sparing agents’ (SSA) or remission maintenance drugs (especially
after relapse), but their long-term efficacy requires further evaluation [8,
9•, 10••, 144, 150–152, 157–160]. MTX was specifically assessed in a
recent retrospective small study by Della-Torre et al. and was reported to
be effective in maintaining clinical and serological responses induced by
glucocorticoids, enabling a substantial reduction in the overall dose of
steroids in all patients and their withdrawal in six of ten patients within
6–12 months [161]. None of these patients had neurological disease
secondary to IgG4-RD, and it should be noted that others have reported
conflicting results of SSA use (predominantly MTX) in neurological dis-
ease caused by IgG4-RD [15, 63, 64, 69–71, 83, 118, 162, 163].
For those patients with IgG4-RD that is either refractory to glucocor-
ticoids or which relapses, B cell depletion with rituximab (RTX) appears
to represent a promising treatment [133, 149, 160, 164–166]. Patients
treated with RTX (typically two 1-g intravenous infusions given 2 weeks
apart) have generally demonstrated prompt clinical, radiological and
serologic responses, enabling rapid glucocorticoid taper and leading to a
swift decline in serum IgG4 [149, 160, 164, 166]. Moreover, the decline
in serum IgG4 appears to be more pronounced than the other IgG
subclasses, suggesting that one potential mechanism of RTX efficacy in
IgG4-RD is through interference with the repletion of short-lived plasma
cells that are producing IgG4, although it also appears to be efficacious in
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the group of patients with normal serum levels of IgG4 [133, 149, 164,
166]. RTX has been shown to be effective in controlling pancreatic and
extra-pancreatic IgG4-RD in two recent studies [133, 166]. One was a
prospective single-arm open-label trial and included patients with multi-
system disease, although none had neurological involvement
(NCT01584388) [133]. The other was a retrospective cohort study that
also included patients with multisystem disease, but only 2 of 60 patients
had CNS disease [166].
The prospective trial was conducted in a high-risk group of patients
(multi-organ involvement, prior relapse, previous exposure to steroids
and failure of previous SSA), and the results are reassuring; 97%
responded, with response generally observed after 2 weeks and sustained
for 6 months. At 6 and 12 months after RTX, only 10% of the partici-
pants were on glucocorticoid treatment, thereby avoiding steroid-related
adverse effects in a population of patients that may be particularly
vulnerable. Retreatment with RTX for relapses was deemed necessary in
13% (4/30) during the 12-month period after enrolment. In the retro-
spective cohort, clinical response was seen in 95% of the patients, but
37% relapsed following successful treatment [151]. Predictors of disease
relapse were high baseline values of IgG4, IgE and the total eosinophil
count. Additional reports have emerged of RTX being effective in a
number of cases of IgG4-RD affecting the CNS, generally pachymeningitis
[15, 61, 66, 70, 112, 163].
Serial treatments with RTX (e.g. 1 g every 6 months) may lead to progressive
decline in serum IgG4 concentrations and better disease control, although this
observation needs confirmation [133, 149, 160, 167] and the possibility that
patients who do not benefit from RTX are underreported should be considered.
Apart from pharmacological therapy, some patients may need urgent surgi-
cal intervention (e.g. laminectomy) in the face of ongoing neurological symp-
toms (e.g. paraparesis), and this has been more frequently reported in spinal
pachymeningitis. In fact, some of these patients have been treated with surgery
alone, without concomitant glucocorticoid therapy [58, 168].
To assess the response to treatment, there is general agreement that one
should use a combination of clinical, radiological and serological findings
[10••]. An IgG4 responder index has been developed that takes into account
disease activity across a full spectrum of potential organ involvement, the serum
IgG4 concentration, the need for treatment on an urgent basis, the recording of
damage in organ systems and the cumulative steroid dose over the preceding
28 days, but whilst the potential utility of such a score is acknowledged, this
particular tool requires validation [169].
Conclusion
IgG4-RD is a systemic disease of unknown cause that affects virtually every
organ system, and neurological manifestations have been increasingly
recognised and reported. The most common of these are hypophysitis and
pachymeningitis, which may be life-threatening, although treatable. Therefore,
the differential diagnosis of IgG4-RD must be considered when a patient
presents with signs or symptoms suggestive of hypophysitis or pachymeningitis,
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and special attention should be placed to other clues that may suggest IgG4-RD
(e.g. retroperitoneal fibrosis, sialadenitis and dacryoadenitis). Glucocorticoids
are usually effective in the induction of remission, although a number of
patients relapse. In this regard, retreatment with glucocorticoids and/or a SSA
or RTX is usually necessary, although the optimal treatment strategy remains
uncertain. There is a pressing need for clinical trials to address this as the long-
term side effects of glucocorticoids add significant morbidity. In the future, new
insights derived from a more complete understanding of the pathogenesis of
IgG4-RD may facilitate the development of more effective and better targeted
pharmacological options.
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